Resumen de acción ACRS
Aclaris Therapeutics, Inc., empresa biofarmacéutica en fase clínica, se dedica al desarrollo de nuevos fármacos candidatos para enfermedades inmunológico-inflamatorias en Estados Unidos.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Aclaris Therapeutics, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.22 |
| 52 Week High | US$11.12 |
| 52 Week Low | US$0.59 |
| Beta | 0.23 |
| 1 Month Change | 2.52% |
| 3 Month Change | -0.81% |
| 1 Year Change | -84.79% |
| 3 Year Change | -94.26% |
| 5 Year Change | -78.82% |
| Change since IPO | -88.96% |
Noticias y actualizaciones recientes
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up
Mar 07Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report
Mar 01Recent updates
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up
Mar 07Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report
Mar 01Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 19Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 11Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results
Aug 10What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today
Aug 08Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Jun 06We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions
Oct 06Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata
Aug 25Aclaris Therapeutics gets a new COO
Aug 01Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
May 28We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
Dec 14Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?
Aug 25Aclaris Therapeutics (ACRS) Investor Presentation - Slideshow
Jun 08Shareholders Will Probably Not Have Any Issues With Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Compensation
May 28Rentabilidad de los accionistas
| ACRS | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | -6.9% | 0.3% | 3.3% |
| 1Y | -84.8% | 12.0% | 25.0% |
Rentabilidad vs. Industria: ACRS obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del 9.5%.
Rentabilidad vs. Mercado: ACRS obtuvo unos resultados inferiores a los del mercado US, que fue del 19.3% el año pasado.
Volatilidad de los precios
| ACRS volatility | |
|---|---|
| ACRS Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: ACRS no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ACRS ha disminuido de 16% a 9% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2012 | 89 | Neal Walker | www.aclaristx.com |
Aclaris Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica que se dedica al desarrollo de nuevos fármacos candidatos para enfermedades inmunológico-inflamatorias en Estados Unidos. La empresa opera a través de dos segmentos, Therapeutics y Contract Research. El segmento terapéutico se dedica a identificar y desarrollar terapias para hacer frente a importantes necesidades no cubiertas de enfermedades inmunoinflamatorias.
Resumen de fundamentos de Aclaris Therapeutics, Inc.
| Estadísticas fundamentales de ACRS | |
|---|---|
| Capitalización bursátil | US$86.94m |
| Beneficios(TTM) | -US$77.26m |
| Ingresos (TTM) | US$31.12m |
2.8x
Ratio precio-ventas (PS)-1.1x
Ratio precio-beneficio (PE)¿Está ACRS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ACRS | |
|---|---|
| Ingresos | US$31.12m |
| Coste de los ingresos | US$116.44m |
| Beneficio bruto | -US$85.32m |
| Otros gastos | -US$8.05m |
| Beneficios | -US$77.26m |
Últimos beneficios comunicados
Mar 31, 2024
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.08 |
| Margen bruto | -274.16% |
| Margen de beneficio neto | -248.28% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado ACRS a largo plazo?
Ver rendimiento histórico y comparativa